CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.47B, above the global median of $1.15B
- PositionDebt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)
- Interpretations7 currently firing — 7
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.56%
Annual Rate
INR 7.55Paid unknown
Payout Ratio
43.2%Sustainable
Last Ex-Dividend
Jul 23, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
140.67BINR1.47B · vs all stocks (USD)
Trailing P/E
53.59xvs Biotechnology peers
Revenue (TTM)
10.55BINR110.55M · vs all stocks (USD)
Profit Margin
24.73%vs Biotechnology peers
Beta
0.4210xvs all stocks
52-Week Change
-29.00%vs all stocks
Forward Annual Dividend Yield
0.56%vs all stocks
Market Capitalization
140.67BINR1.47B · vs all stocks (USD)
Enterprise Value
134.45BINR1.41B · vs all stocks (USD)
Trailing P/E
53.59xvs Biotechnology peers
Forward P/E
32.30xvs Biotechnology peers
Price to Sales (TTM)
13.15xvs Biotechnology peers
Price to Book (MRQ)
6.90xvs Biotechnology peers
Enterprise to Revenue
12.75xvs Biotechnology peers
Enterprise to EBITDA
35.67xvs Biotechnology peers
Gross Margin
73.68%vs Biotechnology peers
Profit Margin
24.73%vs Biotechnology peers
Operating Margin
33.84%vs Biotechnology peers
Return on Assets (TTM)
8.91%vs Biotechnology peers
Return on Equity (TTM)
13.54%vs Biotechnology peers
Revenue (TTM)
10.55BINR110.55M · vs all stocks (USD)
Revenue per Share (TTM)
100.83INRUpdated Jul 16, 2026Quarterly Revenue Growth
-24.10%vs Biotechnology peers
Gross Profit (TTM)
6.77BINR70.90M · vs all stocks (USD)
EBITDA (TTM)
4.23BINR44.30M · vs all stocks (USD)
Net Income (TTM)
2.61BINR27.34M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-36.80%vs Biotechnology peers
Operating Cash Flow (TTM)
2.67BINR27.97M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
1.37BINR14.40M · vs all stocks (USD)
Forward Annual Dividend Rate
7.55INRUpdated Jul 16, 2026Forward Annual Dividend Yield
0.56%vs all stocks
Trailing Annual Dividend Rate
7.55INRUpdated Jul 16, 2026Trailing Annual Dividend Yield
0.56%vs all stocks
Payout Ratio
43.18%vs Biotechnology peers
Minority Interest (Equity)
-19.23MINRFY2026 · Mar 31, 2026Revenue
10.46BINRFY2026 · Mar 31, 2026Cost of Goods Sold
2.60BINRFY2026 · Mar 31, 2026Gross Profit
7.86BINRFY2026 · Mar 31, 2026Operating Income
3.05BINR31.95M · vs all stocks (USD)
Pre-tax Income
3.45BINRFY2026 · Mar 31, 2026Income Tax Expense
854.18MINRFY2026 · Mar 31, 2026Net Income
2.59BINRFY2026 · Mar 31, 2026EBIT
3.45BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
4.02BINRFY2026 · Mar 31, 2026Selling, General & Administrative
466.67MINRFY2026 · Mar 31, 2026Other Operating Expenses
1.91BINRFY2026 · Mar 31, 2026Non-operating Interest Income
24.63MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
2.82MINRFY2026 · Mar 31, 2026EPS (Basic)
24.78INRFY2026 · Mar 31, 2026EPS (Diluted)
24.78INRFY2026 · Mar 31, 2026Basic Shares Outstanding
105.29MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
105.29MSharesFY2026 · Mar 31, 2026Minority Interests (P&L)
16.77MINRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
3.32BINRFY2026 · Mar 31, 2026Free Cash Flow
2.37BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
121.86MINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
3.45BINRFY2026 · Mar 31, 2026Other Non-cash Items
-21.80MINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
704.53MINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-808.28MINRFY2026 · Mar 31, 2026Capital Expenditures
-950.51MINRFY2026 · Mar 31, 2026Purchase of Investments
-9.47BINRFY2026 · Mar 31, 2026Sale of Investments
8.82BINRFY2026 · Mar 31, 2026Other Investing Activity
143.33MINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-1.45BINRFY2026 · Mar 31, 2026Long-term Debt Payments
-3.81MINRFY2026 · Mar 31, 2026Common Dividends Paid
-1.12BINRFY2026 · Mar 31, 2026Net Financing Cash Flow
-1.12BINRFY2026 · Mar 31, 2026Shares Outstanding
104.62MSharesUpdated Jul 16, 2026Float Shares
26.62MSharesUpdated Jul 16, 2026% Held by Insiders
72.48%vs all stocks
% Held by Institutions
12.36%vs all stocks
Total Cash (MRQ)
4.32BINR45.26M · vs all stocks (USD)
Total Cash per Share (MRQ)
41.28INRUpdated Jul 16, 2026Total Debt (MRQ)
23.16MINR242.67K · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0011xvs Biotechnology peers
Current Ratio (MRQ)
7.39xvs Biotechnology peers
Book Value per Share (MRQ)
192.19INRUpdated Jul 16, 2026Total Assets
22.35BINR234.20M · vs all stocks (USD)
Total Current Assets
12.50BINRFY2026 · Mar 31, 2026Total Liabilities
2.20BINRFY2026 · Mar 31, 2026Total Non-current Assets
9.85BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
505.12MINRFY2026 · Mar 31, 2026Total Current Liabilities
1.69BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
121.86MINRFY2026 · Mar 31, 2026Other Short-term Investments
4.07BINRFY2026 · Mar 31, 2026Accounts Receivable
4.60BINRFY2026 · Mar 31, 2026Inventory
3.26BINRFY2026 · Mar 31, 2026Accounts Payable
1.02BINRFY2026 · Mar 31, 2026Short-term Debt
8.82MINRFY2026 · Mar 31, 2026Other Current Liabilities
123.38MINRFY2026 · Mar 31, 2026Long-term Debt
14.33MINRFY2026 · Mar 31, 2026Common Stock (Book)
104.62MINRFY2026 · Mar 31, 2026Retained Earnings
18.96BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
20.15BINR211.19M · vs all stocks (USD)
52-Week Low
987.05INRUpdated Jul 16, 202652-Week High
1.98KINRUpdated Jul 16, 202652-Week Change
-29.00%vs all stocks
Beta
0.4210xvs all stocks
50-Day MA
1.23KINRUpdated Jul 16, 2026200-Day MA
1.28KINRUpdated Jul 16, 2026Avg 10-Day Volume
9.10KSharesUpdated Jul 16, 2026Avg 30-Day Volume
31.75KSharesUpdated Jul 16, 2026Diluted EPS (TTM)
24.75INRUpdated Jul 16, 20267 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 0×, lower than 95% of its Biotechnology peers (median 0.09×)Notable
Debt-to-equity: 0.00Industry median: 0.09Industry P5: 0.00Peers compared: 261
Financial Health
High structural barrier to entryNotable
Barrier to Entry: 0.61
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.47B, above the global median of $1.15BNotable
Market cap (USD): 1,474,189,592.047Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inspire Medical Systems, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Integra LifeSciences Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Olix Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shandong Xinhua Pharmaceutical Company Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pacific Shuanglin Bio-Pharmacy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Septarna Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Pharma Research Products Co., Ltd
7 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Zozo, Inc.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels
Yealink Network Technology Co., Ltd.
6 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash-Flow Ratios ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net Levels